EQS-News: Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
The new shares are fully subscribed at par value by the Company's wholly owned subsidiary, Relief Therapeutics International SA, and will be listed on the SIX Swiss Exchange on or around July 28, 2021.
- The new shares are fully subscribed at par value by the Company's wholly owned subsidiary, Relief Therapeutics International SA, and will be listed on the SIX Swiss Exchange on or around July 28, 2021.
- Some of the shares will be used for contractually agreed payments to the respective sellers of AdVita Lifescience GmbH ("AdVita") and APR Applied Pharma Research SA ("APR"): approximately 140,000,000 [1] shares and 206,786,784 shares, respectively.
- The remaining new shares will be held as treasury shares for possible future financing transactions, acquisitions, general corporate purposes, and the settlement of possible future contingent milestone payments to the APR and AdVita sellers.
- Jack Weinstein, CFO and Treasurer of Relief, said: "During the course of 2021, we have taken several important steps to transform Relief into a multi-product, revenue-generating company.